Kenneth Gordon to Dermatologic Agents
This is a "connection" page, showing publications Kenneth Gordon has written about Dermatologic Agents.
Connection Strength
8.952
-
IL-23 inhibitors for moderate-to-severe psoriasis. Semin Cutan Med Surg. 2018 Sep; 37(3):158-162.
Score: 0.616
-
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661.
Score: 0.613
-
Treating to Target-A Realistic Goal in Psoriasis? Semin Cutan Med Surg. 2018 Feb; 37(2S):S44-S47.
Score: 0.592
-
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018 01; 178(1):132-139.
Score: 0.587
-
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials. J Am Acad Dermatol. 2017 Dec; 77(6):1030-1037.
Score: 0.579
-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar; 76(3):418-431.
Score: 0.549
-
Translating the Science of Psoriasis. Semin Cutan Med Surg. 2016 Jun; 35(4 Suppl 4):S64.
Score: 0.527
-
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014 Mar; 170(3):705-15.
Score: 0.451
-
Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013 Dec; 169(6):1337-41.
Score: 0.443
-
Systemics to topicals in psoriasis: the unfilled need. Br J Dermatol. 2013 Jul; 169(1):2-3.
Score: 0.431
-
Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009 Sep-Oct; 22(5):431-40.
Score: 0.330
-
Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat. 2007; 18(1):13-8.
Score: 0.275
-
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17; 290(23):3073-80.
Score: 0.222
-
Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf. 2002; 25(13):913-27.
Score: 0.194
-
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021 Feb; 84(2):432-470.
Score: 0.176
-
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2020 Feb; 34(2):301-309.
Score: 0.167
-
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020 Jan; 82(1):161-201.
Score: 0.167
-
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380.
Score: 0.167
-
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr; 80(4):1029-1072.
Score: 0.159
-
Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018 Aug; 32(8):1297-1304.
Score: 0.153
-
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2018 Aug; 79(2):294-301.e6.
Score: 0.150
-
Practical Strategies for Optimizing Management of Psoriasis. Semin Cutan Med Surg. 2018 Feb; 37(2S):S52-S55.
Score: 0.148
-
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value Health. 2017 09; 20(8):1174-1179.
Score: 0.142
-
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016 06 01; 152(6):661-9.
Score: 0.132
-
Patient satisfaction and quality of life in psoriasis and psoriatic arthritis. JAMA. 2014 Dec 24-31; 312(24):2676-7.
Score: 0.119
-
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014 Dec; 71(6):1176-82.
Score: 0.117
-
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012 Apr; 166(4):861-72.
Score: 0.099
-
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012 Mar; 11(3):300-12.
Score: 0.098
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul; 65(1):137-74.
Score: 0.091
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Sep; 61(3):451-85.
Score: 0.081
-
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol. 2006 May; 45(5):605-14.
Score: 0.066
-
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005 May; 152(5):954-60.
Score: 0.061
-
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):425-33.
Score: 0.060
-
Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003 Dec; 139(12):1540-2.
Score: 0.055
-
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023 01; 88(1):40-51.
Score: 0.051
-
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 02 06; 397(10273):487-498.
Score: 0.046
-
The Evolving Landscape of Psoriasis Treatment. Semin Cutan Med Surg. 2018 Feb; 37(2S):S39-S43.
Score: 0.037